ATE302771T1 - Indolinon-derivative als protein-kinasehemmer - Google Patents

Indolinon-derivative als protein-kinasehemmer

Info

Publication number
ATE302771T1
ATE302771T1 AT02796035T AT02796035T ATE302771T1 AT E302771 T1 ATE302771 T1 AT E302771T1 AT 02796035 T AT02796035 T AT 02796035T AT 02796035 T AT02796035 T AT 02796035T AT E302771 T1 ATE302771 T1 AT E302771T1
Authority
AT
Austria
Prior art keywords
sup
kinase inhibitors
protein kinase
indolinone derivatives
indolinone
Prior art date
Application number
AT02796035T
Other languages
English (en)
Inventor
John H Griffin
Roger Briesewitz
Jonathan W Wray
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE302771T1 publication Critical patent/ATE302771T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02796035T 2001-12-27 2002-12-20 Indolinon-derivative als protein-kinasehemmer ATE302771T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34374601P 2001-12-27 2001-12-27
US34381301P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE302771T1 true ATE302771T1 (de) 2005-09-15

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796035T ATE302771T1 (de) 2001-12-27 2002-12-20 Indolinon-derivative als protein-kinasehemmer

Country Status (21)

Country Link
US (3) US6686362B2 (de)
EP (1) EP1458713B1 (de)
JP (1) JP4363985B2 (de)
KR (1) KR100965519B1 (de)
CN (1) CN1290844C (de)
AT (1) ATE302771T1 (de)
AU (1) AU2002360753B2 (de)
BR (1) BR0215360A (de)
CA (1) CA2470480C (de)
CO (1) CO5611126A2 (de)
DE (1) DE60205776T2 (de)
DK (1) DK1458713T3 (de)
ES (1) ES2247411T3 (de)
HU (1) HUP0500111A3 (de)
IL (1) IL162203A0 (de)
MX (1) MXPA04006271A (de)
NO (1) NO327550B1 (de)
NZ (1) NZ533219A (de)
PL (1) PL208283B1 (de)
RU (1) RU2316554C2 (de)
WO (1) WO2003057690A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
AU2004284084A1 (en) 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
CN101340909B (zh) 2005-10-18 2012-01-11 詹森药业有限公司 抑制flt3激酶的方法
MX2008013531A (es) 2006-04-20 2009-01-20 Janssen Pharmaceutica Nv Inhibidores de c-fms cinasa.
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007124316A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
AU2007296740B2 (en) 2006-09-11 2012-09-27 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011083124A1 (en) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 receptor antagonists for the treatment or the prevention of pain disorders
CN102812022B (zh) 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
CN104520295B (zh) 2012-08-07 2017-07-18 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
EP2882757B1 (de) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Verfahren zur herstellung heterocyclischer esterderivate
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
BR112015016282A2 (en) 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanib for treatment of mutated flt3 proliferative disorders
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
EP3174859B1 (de) 2014-07-31 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Flt3-rezeptorantagonisten
EP3254698A1 (de) 2016-06-08 2017-12-13 Universite De Montpellier Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
HK1257195A1 (zh) 2016-11-02 2019-10-18 安罗格制药有限责任公司 用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼
CA3062981A1 (en) 2017-05-17 2018-11-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
IL139934A (en) 1998-05-29 2007-10-31 Sugen Inc History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
JP2002533360A (ja) 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AU6998000A (en) 1999-08-27 2001-03-26 Boehringer Ingelheim Pharma Kg Substituted indolinones as tyrosine kinase inhibitors
ES2225231T3 (es) 1999-10-06 2005-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas.
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2001042243A2 (en) 1999-12-08 2001-06-14 Advanced Medicine, Inc. Protein kinase inhibitors
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
EP2277877A1 (de) 2000-08-18 2011-01-26 Millennium Pharmaceuticals, Inc. Quinazolinderivate als Kinasehemmer
WO2002055517A2 (en) 2000-12-20 2002-07-18 Jingrong Cui 4-(hetero)aryl substituted indolinones
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
JP2007513967A (ja) 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物

Also Published As

Publication number Publication date
US20030171378A1 (en) 2003-09-11
ES2247411T3 (es) 2006-03-01
CA2470480C (en) 2010-12-14
HUP0500111A2 (hu) 2005-07-28
DE60205776T2 (de) 2006-06-14
CN1608063A (zh) 2005-04-20
KR20040070283A (ko) 2004-08-06
EP1458713B1 (de) 2005-08-24
HK1068886A1 (en) 2005-05-06
DK1458713T3 (da) 2005-10-31
BR0215360A (pt) 2004-12-14
PL208283B1 (pl) 2011-04-29
NO20042926L (no) 2004-07-08
US6686362B2 (en) 2004-02-03
US7060703B2 (en) 2006-06-13
CN1290844C (zh) 2006-12-20
JP2005514420A (ja) 2005-05-19
PL369602A1 (en) 2005-05-02
US20040198804A1 (en) 2004-10-07
RU2004122918A (ru) 2005-03-27
AU2002360753A1 (en) 2003-07-24
EP1458713A1 (de) 2004-09-22
NO327550B1 (no) 2009-08-10
MXPA04006271A (es) 2004-10-04
NZ533219A (en) 2005-10-28
US20060142281A1 (en) 2006-06-29
DE60205776D1 (en) 2005-09-29
WO2003057690A1 (en) 2003-07-17
KR100965519B1 (ko) 2010-06-23
IL162203A0 (en) 2005-11-20
HUP0500111A3 (en) 2009-10-28
AU2002360753B2 (en) 2008-08-21
CO5611126A2 (es) 2006-02-28
JP4363985B2 (ja) 2009-11-11
US7223783B2 (en) 2007-05-29
RU2316554C2 (ru) 2008-02-10
CA2470480A1 (en) 2003-07-17

Similar Documents

Publication Publication Date Title
ATE302771T1 (de) Indolinon-derivative als protein-kinasehemmer
CY1111599T1 (el) Αναστολεις κινασης θειενοπυριδινης και φουροπυριδινης
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
CY1108032T1 (el) Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE353320T1 (de) Tricyclische proteinkinasehemmer
CY1106165T1 (el) Παραγωγα ινδολινονης για την τροποποιηση της c-kit πρωτεϊνικης τυροσινικης κινασης
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE195734T1 (de) Aryliden-und heteroaryliden-oxindol derivate als tyrosin kinase inhibitoren
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
ATE554087T1 (de) Neue kinaseinhibitoren
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
DE60112742D1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
DE60206762D1 (de) Hexahydroazepino[4,5-g]indole und -indoline als 5-ht-rezeptor-liganden
ATE540951T1 (de) Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1458713

Country of ref document: EP